There is a slight risk associated with trading before and after the market open. Due to lower liquidity and higher volatility, extended-hours trading may result in wider spreads on particular security due to the release of critical financial information after regular trading hours. After-hours trades for Gossamer Bio Inc (GOSS) shows that investor sentiment remained broken, with the stock’s consolidated last price falling by -$0.0222, or -2.74%, to $0.7885. The Gossamer Bio Inc has recorded 9,503 volume in the after hours trading session. Recently, Yahoo Finance discussed the stock, revealing that Gossamer Bio Announces Third Quarter 2023 Financial Results and Provides Business Update.
This NASDAQ-listed company operates within the Biotechnology industry segment, falling under the Healthcare sector. At the end of the last regular session, the stock closed at $0.81 and fluctuated between $0.8289 as its day high and $0.6587 as its day low. The current market capitalization of Gossamer Bio Inc is $182.74M. A total of 4.96 million shares were traded on the day, compared to an average of 2.05M shares.
Insider trades can also provide insight into a stock’s future direction. During the recent three months, GOSS has seen 0 BUY and 0 SELL insider trades, representing the acquisition of 0 and the disposition of 0 shares. Over the last 12 months, there were 9 BUYs and 4 SELLs from insiders. Insiders purchased 1,609,772 shares during that period but sold 22,970.
In the most recent transaction, Giraudo Bryan bought 200,000 shares of GOSS for 0.56 per share on Nov 13. After the transaction, the COO/CFO now owns 380,010 company shares. In a previous transaction on Jun 22, Aranda Richard sold 1,814 shares at 1.29 per share. GOSS shares that Chief Medical Officer owns now total 197,574.
Among the insiders who bought shares, Giraudo Bryan acquired of 55,000 shares on Apr 04 at a per-share price of $1.02. This resulted in the COO/CFO holding 125,990 shares of GOSS after the transaction. In another insider transaction, Hasnain Faheem bought 440,500 shares at $1.14 per share on Mar 22. Company shares held by the President & CEO now total 4,495,897.
Even though price targets are rarely accurate, they do tend to exert some kind of influence from time to time and are often considered important by markets. According to analysts who have offered 12-month price targets for GOSS in the last 3 months, the mean price target is $5.34 with high estimates of $15.00 and low estimates of $0.50. In terms of 52-week highs and lows, GOSS has a high of $10.46 and a low of $0.45.
As of this writing, GOSS has an earnings estimate of -$0.21 per share for the current quarter. EPS was calculated based on a consensus of 10 estimates, with a high estimate of -$0.16 per share and a lower estimate of -$0.29. The company reported an EPS of -$0.45 in the last quarter, which was 8.20% higher than expectations of -$0.49.
Balance Sheet Annually/Quarterly
In a balance sheet, you can see what assets and liabilities the company has, as well as how much equity investors have invested. These figures can be used to calculate a company’s financial ratios to give investors a better idea of its prospects. GOSS’s latest balance sheet shows that the firm has $325.22M in Cash & Short Term Investments as of fiscal 2021. There were $185.24M in debt and $39.86M in liabilities at the time. Its Book Value Per Share was $0.46, while its Total Shareholder’s Equity was $121.46M.
The risks associated with pre-market and after-hours trading may be slightly higher than the regular market hours. The reason is that extended-hours trading may result in wider spreads for particular security due to lower liquidity and higher volatility as issuers often announce critical financial information outside regular trading hours. Currently, 0 analysts are providing their opinions on the stock. On a scale of 1 to 5, with 1 being Sell and 5 being Buy, the average analyst rating for GOSS is Buy with a score of 4.00.